Neoplasms

All Conditions

Heart and Blood Diseases

Digestive System Diseases

Carcinoma

Hypertension

Carcinoma, Hepatocellular

Hypertension, Portal

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Vascular Diseases

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Amino Acids

Bevacizumab

Chlorotrianisene

Liver Extracts

Endothelial Growth Factors

Mitogens

Tyrosine Kinase Inhibitors

Tyrosine

A CT-based HVPG Score, whose computed formula was: 17.37-4.91\*ln(Liver/Spleen volume ratio) +3.8\[If presence of peri-hepatic ascites\],was used to diagnose CSPH (HVPG\>10mmHg) with a cut-off value 11.606.

TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.

TACE ± Systemic therapy

Gao-Jun Teng, M.D.

Yu-Qing Wang

Gao-Jun Teng

Xiaolong Qi, M.D.

This study aims to evaluate the impact of non-invasive CT-based Hepatic Venous Pressure Gradient (HVPG) assessment on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the second leading cause of cancer-related deaths globally. Transarterial chemoembolization (TACE) is recommended as standard therapy for intermediate-stage HCC according to the current guidelines and is also the most widely used in advanced HCC in real-world practice. Portal hypertension increases the risk of hepatic decompensation, which impairs survival in patients with HCC. Clinically significant portal hypertension is defined as \>10 mmHg increase in the hepatic vein pressure gradient (HVPG), and the current gold standard for its assessment is direct measurement, through a transjugular approach. However, due to its invasive character and high effort, HVPG measurement is not a standard tool in the initial diagnostic evaluation of patients with HCC. This study aims to evaluate the impact of non-invasive CT-based Hepatic Venous Pressure Gradient (HVPG) assessment on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).

CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Non-invasive CT-based Hepatic Venous Pressure Gradient Assessment for Predicting the Prognosis of Hepatocellular Carcinoma With Transarterial Chemoembolization (CHANCE-CHESS 2302): A Multicenter Retrospective Study

The OS is defined as the time from the initiation of any treatment to death due to any cause.

The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per mRECIST.

The PFS is defined as the time from the initiation of any treatment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first.

Zhongda Hospital

President

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)	NCT05704192	Hepatocellular ... Portal Hyperten...	TACE ± Systemic...	18 Years -	Zhongda Hospital
CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)	NCT05704192	Hepatocellular ... Portal Hyperten...	TACE ± Systemic...	18 Years -	Zhongda Hospital

Spots Global Cancer Trial Database for tace ± systemic therapy